Buch, Englisch, Band 18, 158 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 271 g
Buch, Englisch, Band 18, 158 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 271 g
Reihe: Resistance to Targeted Anti-Cancer Therapeutics
ISBN: 978-3-030-08652-7
Verlag: Springer International Publishing
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma.- Biology and Pathology of B-cell lymphoma.- Resistance to Y-90 Ibritumomab Tiuxetan Therapy.- Features of Ibritumomab as Radionuclide Therapy.- Radiological Evaluation of Response and Resistance of Ibritumomab.- Characteristics of Ibritumomab as Radionuclide Therapy Agent.- Resistance and Heterogeneity of Intratumoral Antibody Distribution.- Radiation Dosimetry in Ibritumomab Therapy.- Combining RAIT and immune-based therapies to overcome resistance in cancer?.- Prospects for enhancing efficacy of radioimmunotherapy.- Index.